CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a biopharmaceutical company, has announced the addition of two renowned inflammatory bowel disease (IBD) specialists, Bruce Sands, MD, MS, and Florian Rieder, MD, to its Clinical Advisory Board (CAB). These appointments are aimed at strengthening the company's development of novel gastrointestinal therapeutics, particularly the advancement of its lead asset, PALI-2108, intended for ulcerative colitis treatment.
Dr. Sands brings extensive experience from his tenure at Mount Sinai and Massachusetts General Hospital. His pioneering work on infliximab for ulcerative colitis and the ACCENT II study on Crohn's disease positions him as a valuable advisor for Palisade Bio's endeavors. Dr. Rieder's expertise, particularly in intestinal fibrosis associated with IBD, complements the CAB as he leads the international Stenosis Therapy and Research (STAR) Consortium and contributes to European Crohn’s and Colitis Organization (ECCO) guidelines.
The CEO of Palisade Bio, J.D. Finley said, "We are committed to advancing the treatment landscape for Inflammatory Bowel Disease (IBD) and believe that the appointment of these preeminent key opinion leaders will assist in the development of a precision approach for IBD treatment."
Palisade Bio's focus on serious chronic gastrointestinal diseases aligns with the company's strategic plan to transform the treatment landscape through targeted therapeutics. The upcoming Phase 1 clinical study for PALI-2108 is set to launch next year, with the aim of addressing unmet needs in ulcerative colitis treatment.
The information in this article is based on a press release statement from Palisade Bio, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.